IntegraGen is conducting groundbreaking research in the area of oncology biomarkers and the development of an advanced scientific software program that will aid in the interpretation of genome sequencing data obtained from cancer patients. Click here for the latest updates on our progress.

Technical Validation Data for miR-31-3p test Published in Biomarker Insights

IntegraGen is pleased to announce that a comprehensive summary of the results of validation studies associated with the company’s proprietary miR-31-3p expression test has been published online in Biomarker Insights following peer-review.

The paper entitled “Technical validation of a reverse-transcription quantitative polymerase chain reaction in vitro (…)  » 

IntegraGen announces miR-31-3p publication in Oncotarget

IntegraGen announces that results from an analysis of miR-31-3p expression in tumor samples from patients enrolled in the NEW EPOC clinical trial have been published online in Oncotarget. The paper entitled “Association between miR-31- 3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a (…)  » 

IntegraGen’s Scientific Advisory Board Meets to Review latest miR-31-3p data

IntegraGen’s oncology Scientific Advisory Board (SAB) recently met at the venue of the 2016 American Society of Oncology’s (ASCO) Gastrointestinal Cancers Symposium in San Francisco to review the results from the latest clinical study exploring the predictivity of miR-31-3p on the efficacy of anti-EGFR therapy in all-RAS wild-type metastatic colorectal cancer (…)  »